Viruses as key modulators of the TGF-β pathway; a double-edged sword involved in cancer

Habibollah Mirzaei1,2 | Ebrahim Faghihloo3

1 Department of Virology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, IR Iran
3 Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence
Ebrahim Faghihloo, Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Email: faghihloo@sbmu.ac.ir; faghihloo@gmail.com

1 INTRODUCTION

With approximately a million cancer-caused deaths per year, onco- genic viruses are a major cause of cancer-related mortality; indeed, approximately 10% to 18% of human malignancies are linked to viruses, globally.1,2 To date, 7 human viruses, namely, HCV, HBV, HPV, EBV, HTLV-1, Kaposi’s sarcoma-associated herpes virus (KSHV), and Merkel cell polyomavirus (MCV) have been etiologically involved in the development of human cancers.3 In addition, there are other viruses implicated in human carcinogenesis whose causal roles have yet to be fully confirmed.4 To prevent and manage viral-mediated cancers appropriately, the molecular events underlying the interactions between both oncogenic viruses and cells should be clearly understood. Transforming growth factor (TGF)-β signaling pathway is a key signaling network, with a diverse range of pathophysiological activities, playing essential roles in processes such as cell proliferation and differentiation, apoptosis, inflammation, angiogenesis, epithelial-to-mesenchymal transition (EMT), and tumorigenesis.5 Accordingly, it is not yet to be fully confirmed.4 To prevent and manage viral-mediated cancers appropriately, the molecular events underlying the interactions between both oncogenic viruses and cells should be clearly understood. Transforming growth factor (TGF)-β signaling pathway is a key signaling network, with a diverse range of pathophysiological activities, playing essential roles in processes such as cell proliferation and differentiation, apoptosis, inflammation, angiogenesis, epithelial-to-mesenchymal transition (EMT), and tumorigenesis.5 Accordingly, it is not

ABBREVIATIONS: EMT, Epithelial-to-mesenchymal transition; MCV, Merkel cell polyomavirus; TGF-β, Transforming growth factor-β; TGFβRI, TGF-β receptor I; LOH, Allelic loss of heterozygosity; R-SMADs, Receptor-regulated SMADs; I-SMADs, Inhibitory SMADs; JNK, Jun N-terminal kinase; HCC, Hepatocellular carcinoma; CLD, Chronic liver disease; THBS, Thrombospondin; GRP94, Glucose-regulated protein 94; TβRE, TGF-β-responsive element; ECM, Extracellular matrix; pSMAD3L, Linker-phosphorylated SMAD3; PPM1a, Protein phosphatase magnesium dependent 1A; LMP, Latent membrane protein; EBNA, EBV nuclear antigens; KS, Kaposi’s sarcoma; MCD, Multicentric Castleman’s disease; PEL, Primary effusion lymphoma; Vflip, Viral Fas-associated death domain IL-1β-converting enzyme inhibitory protein; vCyc, Viral cyclin; LANA, Latency-associated nuclear antigen; ATL, Adult T-cell leukemia; HBZ, HTLV-1 bZIP factor; SBE, SMAD binding elements; MMP-2, Matrix metalloproteinase 2; EVT, Extravillous cytotrophoblast; HCE, Human corneal epithelial cells; SARS-CoV, Severe acute respiratory syndrome-associated coronavirus; PIPpro, Papain-like protease; PAI-1, Plasminogen activator inhibitor-1; TLR-3, Toll like receptor 3; AV, Adenovirus; IFP, Idiopathic pulmonary fibrosis; Huh-7, Human hepatocellular carcinoma cells; EBOV, Ebola virus; Treg, Regulatory T cells
surprising that its loss of regulation can contribute to a broad range of pathologies such as cancer. In this regard, the present review focuses on describing the modulation of this pivotal pathway by either tumor-caused or tumor-associated viruses. It first outlines the key aspects of the TGF-β pathway, before focusing on the existing literature on the subject of viral interference with TGF-β signaling.

2 | THE TGF-β SIGNALING PATHWAY

TGF-β signaling plays vital roles in both biological processes and diseases. Regarding tumorigenesis, it exhibits a dual role by demonstrating anti-tumor effects (through inhibiting the proliferation and inducing apoptosis) and pro-oncogenic activities (via inducing EMT and tumor metastasis) during early and late stages of oncogenesis, respectively. This pathway mediates its functions through TGF-β cytokines whose binding to type II and type I serine-threonine kinase receptors (known as TGFbRI and TGFbRII, respectively) results in the activation of 2 different downstream pathways; SMAD-dependent and SMAD-independent pathways. Indeed, the effects of TGF-β are often controlled by 3 TGFβ ligands, TGF-β1, TGF-β2, and TGF-β3, secreted as latent protein complexes, required to be activated by proteolytic cleavage before binding to receptors. Activated TGF-β interacts with and activates TGFbRII, leading to the phosphorylation of TGFbRI, whose activation results in signal transduction via recruiting and phosphorylating receptor-regulated SMADs (R-SMAD), SMAD2 and SMAD3, which subsequently interact with Co-SMADs (eg, SMAD4) to form the activated SMADs complex, that thereafter, translocate into the nucleus, wherein it exerts its regulatory effects on the expression of target genes, by recruiting other co-activator or co-repressor factors for transcription (eg, p300, CBP) (Figure 1). Furthermore, TGFbRIII is another TGF-β receptor, playing a coreceptor role for TGFbRII. SMAD-dependent cascade, as the major TGF-β signaling mediator, conveys signals from TGFbRI to the nucleus in a linear pathway, a process blocked by inhibitory SMADs (I-SMADs); for instance, SMAD7 represses this pathway either via interacting with activated TGFbRI, and hence, preventing R-SMAD activation or through recruiting SMURF2, a ubiquitin-ligase, which promotes SMAD2 and TGFbRI decrease and downmodulates SMAD3 function. Perturbations of this cascade can lead to tumorigenesis and tumor promotion via either direct or indirect effects on key cellular process. For example, SMAD4 and TGFbRII were shown to be often disrupted by mechanisms such as allelic loss of heterozygosity (LOH) and mutation in multiple carcinomas. Similarly, disturbed SMAD4 has also been observed in a number of malignancies, representing a tumor suppressor role for this pathway. In addition to the SMADs cascade, which plays the central role, TGF-β can also interact with other signaling cascades, those mediated independently of the SMAD factors, such as p38 MAP kinases, c-Jun N-terminal kinase (JNK), Ras-ERK, PI3K-Akt, and small GTPases (eg, RhoA), in a cell type-specific manner.

3 | TUMOR-CAUSED VIRUSES AND TGF-β SIGNALING

3.1 | Hepatitis C virus

HCV is a member of the Flaviviridae family with a single stranded RNA, acting as a major cause of liver diseases, including fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). In patients with chronic HCV infection, chronic liver disease (CLD) occurs in 50% of the cases leading to 5% to 20% cirrhosis, of which, 1% to 2% result in HCC, a pathology causing for approximately 600 000 deaths per year. Dysregulation of TGF-β signaling has been implicated in the pathogenesis of all stages of the liver diseases, a cytokine whose upregulated...
level has been reported both in liver tissue and serum of patients with chronic HCV infection and HCC.23 Recently, Jee found high levels of expressing TGF-β in hepatocytes of HCV patients, as well as, in HCV-infected hepatocytes cultured in vitro, as that of cultured cells was sufficient to activate liver fibrosis-associated cells, hepatic stellate cells (HSC), a new mechanism underlying liver fibrogenesis.24 Accordingly, the HCV E2 protein was reported as cause of this overproduction, by acting through glucose-regulated protein 94 (GRP94) mediated NF-κB activation, which proposed GRP94 as a potential target for preventing HCV-caused liver cirrhosis. Relevant in this regard, other investigations have shown an upregulated level of TGF-β either directly by HCV factors, in particular core protein, or via NF-κB and oxidative/ER stress activation.25-29 Taniguchi indicated TGF-β upmodulation at the transcriptional levels by HCV core protein.28 Furthermore, HCV core protein also increases active TGF-β levels by thrombospondin (THBS), an anti-angiogenic factor whose function is mediated in part through activating the latent form of TGF-β, and thus SMAD2/3 phosphorylation, indicating TGF-β signaling activation.29 Similarly, HCV increases ROS production, which in turn activates the p38 MAPK, JNK, and ERK pathways, leading to NFκB activation that induces TGF-β production.30 Conversely, HCV N55A protein was able to block a pivotal transcriptional activator for TGF-β gene expression, known as AP-1, through interrupting the Ras-ERK pathway.24 In addition to overexpression or activation of TGF-β cytokine, HCV also interferes with downstream TGF-β signaling components and mediators.31-33 TGF-β arrests cell cycle promotion by upmodulation of inhibitory factors such as p21, a key role whose inhibition exerts a fundamental effect on tumor progression.34 Recently, Choi showed HCV N55A protein acts as a negative modulator, where it interacts with TGFβRI, resulting in inhibition of SMAD2 phosphorylation and SMADs complex formation and then in downmodulation of p21 expression.31 Furthermore, HCV core protein suppresses TGF-β-induced p21 overexpression in a transcriptional-dependent manner. In fact, HCV core protein functions through the TGF-β-responsive element (TβRE) positioned in the p21 promoter region to repress the p21 promoter by suppression of TGF-β pathway; a mechanism by which HCV results in cell growth induction.32 In the same way, Cheng showed 2 physical interactions between the HCV core and NS3 proteins with SMAD3 factor, which was shown to suppress the SMAD3-mediated transcriptional activation of target genes via reducing the SMAD3 binding ability to the SMAD binding elements (SBE) located in the promoter regions.33 Pavio by assessing core variants isolated from both tumoral and non-tumoral tissues of the same HCC patient reported in contrast to tumor derived variants, which block TGF-β signaling, no such effects were exerted by non-tumoral ones.35 Additionally, their findings demonstrated a direct interaction between core and SMAD3, which in turn inhibited the DNA-encoding activity of SMAD3. Hence, it could be concluded that during chronic infection, those viral variants would be selected that provoke cell transformation via enhancing resistance to anti-proliferative activities of TGF-β. Battaglia similarly found HCC-derived HCV core proteins are capable of shifting TGF-β responses from anti-tumor to pro-tumor effects via reducing SMAD3 signaling.36 This duality of function of TGF-β in tumorigenesis was also further observed in another study, where a TGFβRI-independent SMAD3 activation by TGF-β resulted in a shift of TGF-β activity from tumor-suppressor to fibrogenic in HCV-chronically infected patients; in these patients, TGF-β activated c-JNK, which in turn phosphorylated SMAD3 into linker-phosphorylated SMAD3 (pSMAD3L) and led to extracellular matrix (ECM) deposition via upmodulating plasminogen activator inhibitor 1 (PAI-1), a process, which increased during liver disease course from chronic hepatitis through cirrhosis to HCC.37 Interestingly, HCV may be able to indirectly block TGF-β mediated-apoptosis via inducing the PI3K-Akt survival pathway. This PI3K-Akt-mediated survival signal could be directed by N55A, which is capable of downmodulating PTEN, an inhibitor of the PI3K-Akt pathway.38 HCV also affects TGF-β signaling via interacting with SMURF2, a key negative regulator of the TGF-β pathway. HCV NS5A-4A targets SMURF2, resulting in enhanced SMAD2/3 phosphorylation and then in increased TGF-β signaling, an event, which is inhibited by SMURF2 overexpression.14 Taken together, these observations show how TGF-β signaling can be both negatively and positively regulated by HCV to affect the pathogenesis of HCV infection outcomes (Figure 2).

3.2 | Hepatitis B virus

HBV is a DNA virus pertained to the Hepadnaviridae family, known as another major risk factor for cirrhosis and HCC progression.39,40 HBV chronic infection is currently estimated to influence almost 240 million people, globally, of which approximately 10% have an increased risk of developing cirrhosis and HCC.5,41 Similar to HCV, HBV also interacts with the TGF-β pathway, a phenomenon mainly mediated by HBV X protein (HBx), which may exert diverse effects on the pathogenesis of the HBV-mediated liver pathologies.7,21,42,43 (Figure 3). Evidence by Murata further supported the hypothesis that the TGF-β pathway is directly involved in liver tumorigenesis, where HBx was shown to switch the target of hepatocytic TGF-β signaling from the TGFβRI/ pSmad3C/p21 anti-tumor pathway to the JNK/pSmad3L/c-Myc tumor supportive pathway in the early stages of liver carcinogenesis.43 Subsequently, the same result was reported by WU investigating the effect of TGF-β on HBx-expressing well-differentiated HCC cells.42 As a result, the JNK/pSmad3L pathway can be regarded as a potential candidate toward preventing and treating HBV-mediated HCC. It is thought the upregulated TGF-β pathway enhances the invasive and metastatic potential of HCC cells, by suppressing E-cadherin expression and promoting regulatory T cells (Treg) induction.7,21,44,45 In this respect, Liu suggested a new mechanism underlying the pathogenesis of HBV-caused HCC; HBx downmodulates protein phosphatase magnesium-dependent 1A (PPM1a) levels, resulting in overactivation of the TGF-β signaling pathway.7 In fact, HBx was shown to promote the degradation of PPM1a, a p-Smad2/3 phosphatase required for terminating TGF-β signaling, through elevating its ubiquitination. Furthermore, Yoo showed HBx upregulates TGF-β expression by acting through the Egr transcription factors binding sites.45 A study by Lee also demonstrated that HBx directly interacts with SMAD4 leading to the SMAD complex stabilization and enhanced TGF-β signaling.45 In this way, HBV may affect cancer invasion in HCC, by upmodulating the TGF-β pathway. Moreover, HBx has also been shown to prevent TGF-β mediated-apoptosis via upregulating the PI3-kinase signaling pathway activity.47 In addition to HBx, HBV transcripts have also been
implicated in the pathogenesis of HCC. A recent study demonstrated HBV mRNAs could bind to and absorb microRNA 15a/16 to inhibit apoptosis. The importance of this interaction was subsequently highlighted, when the authors interestingly found that SMAD7 acts as a target of miR-15a. Thus, HBV can increase the level of SMAD7 and then block TGF-β signaling and corresponding responses (eg, apoptosis) by downmodulating miR-15a, an attractive molecular target for therapeutic development.

3.3 Human papilloma virus

HPVs are DNA viruses associated with the development of cervical, anal, and head and neck cancers. The majority of cervical cancer is mediated by HPV16 and HPV18 encoding the E6 and E7 oncoproteins. There is a close relationship between HPV infection and the TGF-β pathway in cervical tissues: investigations have reported upmodulated TGF-β levels in HPV-positive cervical cancers compared with HPV-negative ones and have suggested a positive correlation between the expression levels of TGF-β and the HPV E6/E7 oncogenes, which may be due to trans-regulatory functions of the E6/E7 oncoproteins, so that, HPV16 E6/E7 have been shown to enhance TGF-β promoter activity by interacting with an Sp1-binding site placed in the TGF-β core promoter. However, a prominent aspect of malignant transformation in cervical epithelial cells is the progressive loss of TGF-β responsiveness. In this respect, studies demonstrate a contributing role for HPV in the acquisition of TGF-β
resistance in cervical cancer (Figure 4). HPV16 E7 interacts with SMAD2, SMAD3, and SMAD4 leading to inhibition of SMAD3 binding to its DNA targets and then blocking the pathway.54 HPV16 E5 downregulates the TGF-β pathway by lowering the expression of TGFβRII, as well as, by reducing SMAD2 phosphorylation and SMAD4 nuclear translocation, which may play a crucial role in the HPV-induced cervical carcinogenesis.55 Through decreasing the intracellular levels of TIP-2/GIPC, a PDZ protein involved in the expression of TGFβRII, HPV18 E6 was shown to render HeLa cells less sensitive to the anti-growth activities of TGF-β.56 HPV16 E7 was also found to interfere with the growth-inhibitory effects of the cyclin-dependent kinase inhibitors p21Cip1, p27Kip1, and p15INK4B, which are induced by TGF-β.57 Furthermore, Mendoza demonstrated a similar activity for HPV5, a causative agent for skin carcinomas; it was shown that HPV5 E6 could bind to SMAD3 and destabilize the SMAD3/SMAD4 complex.58 Similarly, the cutaneous HPV8 and MmuPV1 (a recently detected HPV) E6 proteins interact with SMAD2/SMAD3 and suppress the TGF-β pathway.59 These findings show that how may these interactions be important in the development of HPV-associated tumors, in particular cervical cancer.

### 3.4 Epstein-Barr virus

EBV is a DNA virus from the Herpesviridae family, involved in Hodgkin’s lymphoma, Burkitt’s lymphoma (as B-cell caneces), nasopharyngeal carcinoma, gastric cancer (as epithelial malignancies),60,61 and autoimmune diseases.62 In these tumors, EBV establishes latent infections, expressing only a subset of viral genes, allowing the virus to affect cellular signaling contributing to oncogenesis.63 EBV may interfere with TGF-β signaling to promote tumorigenesis (Figure 5). Takanashi reported EBV-encoded latent membrane protein 1 (LMP-1) caused loss of TGF-β sensitivity in rodent fibroblasts.64 Arvanitakis earlier had demonstrated LMP-1 inhibited TGF-β-mediated growth suppression in EBV-positive B lymphocytes.65 Subsequently, LMP-1 was indicated to suppress the activation of TGF-β signaling and TGFβ-induced growth suppression via an NF-κB-dependent mechanism.66 Indeed, LMP-1 was suggested to activate NF-κB that in turn and in competition with SMAD proteins interacts with the transcriptional coactivator CBP and p300, those factors essential for SMADs to function as transcriptional effectors. In other words, it seems the LMP-1-mediated inhibitory effect on SMAD-dependent transcription results from inhibition of the transcriptional cofactors involved in SMAD transcriptional function, but not owing to suppression of TGF-β-induced SMAD signaling through mechanisms such as affecting the formation of SMAD heteromers or their DNA binding activities; similarly, LMP-1 suppresses ATF3, a transcriptional repressor induced by SMAD signaling, whose association with SMADs blocks the expression of a growth promoting gene, known as Id1. However, in the absence of this factor, SMAD3 binds to Id1 promoter directly, resulting in Id1 upmodulation.67 In this way, it can be seen how the well-documented “double-edged sword” nature of TGF-β signaling is manipulated by EBV. While, LMP-1 increases the expression of TGF-β and SMAD2 phosphorylation but also blocks SMAD-dependent transcription and TGFβ-mediated cytostasis, and exerts its effects by using the non-SMAD arm of TGF-β signaling; it enhances the secretion of fibronectin through the JNK/SAPK pathway,68 which can contribute to tumor invasiveness. EBV also affects the pathway via EBNA-1 protein, so that, it decreases SMAD2 levels by enhanced protein turnover.69,70 Accordingly, EBNA-1 represses TGF-β-induced transcription of β1g-h3 (a TGF-β-target gene implicated in cell growth, differentiation, and apoptosis), and PAI-1 (a classical target of TGF-β) in carcinoma cells,70 as well as, PTEN (a functional tumor suppressor in Hodgkin lymphoma cells) leading to the growth and survival of these cancer cells.69 EBV-encoded BARF1 is another EBV factor by which

**FIGURE 4** A schematic illustration of the major HPV proteins and corresponding targets, by which HPV modulates the TGF-β signaling pathway.
3.5 | Kaposi’s sarcoma-associated herpes virus

KSHV is a Herpesvirus implicated in the onset of Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma (PEL).\textsuperscript{74} KSHV infection comprises 2 latent and lytic phases, which its transforming properties mainly root from the expression of latent genes such as kaposin, viral micro RNAs, viral Fas- associated death domain IL-1β-converting enzyme inhibitory protein (vFLIP), viral cyclin (vCyc), and latency-associated nuclear antigen (LANA), through enhancing the survival and proliferation of the virus- infected cancer cells.\textsuperscript{75} Dysregulation of TGF-β signaling importantly contributes to cell survival and proliferation in KSHV infection,\textsuperscript{76} and in this way, investigations have reported an interfering role of KSHV-encoded products with this pathway (Figure 6).\textsuperscript{77} TGF-β signaling has been reported to be suppressed by LANA in PEL via the association of this KSHV-encoded protein with the promoter region of TGFbRII and subsequently histone methylation and deacetylation and then downregulation of this receptor, contributing to resistance to the antiproliferative effects of TGF-β.\textsuperscript{77} Choi was able to show that vFLIP and vCyclin upregulate the expression of the oncogenic miR-17-92 cluster that in turn interact with the TGF-β pathway via downmodulating SMAD2 protein.\textsuperscript{75} KSHV not only modifies the expression of cellular miRNAs, but also encodes for viral miRNAs to interact with TGF-β signaling. KSHV-encoded miR-K12-11 targets SMAD5 to block TGFβ signaling, and hence, facilitating cell survival and proliferation. Furthermore, suppression of this viral miRNA eliminates this suppression in B cells infected by KSHV.\textsuperscript{76} Similarly, KSHV miR-K10 variants repress the pathway through targeting TGFbRII, so that its expression is adequate to block TGF-β-mediated cell apoptosis in KSHV-infected PEL cells.\textsuperscript{74} THBS1 has been suggested as another KSHV-encoded miRNAs target; miR-K12 targets this factors resulting in repression of TGF-β signaling.\textsuperscript{78} In addition to the latent proteins, 2 KSHV lytic products also interfere with TGF-β signaling; viral interferon regulatory factor 1 (vIRF-1) was demonstrated to perturb TGF-β-induced transcription and growth arrest through direct interaction with both SMAD3 and SMAD4, leading to interrupting the formation of SMAD3-SMAD4 complex and their DNA binding activity.\textsuperscript{79} Furthermore, by binding to the transcriptional coactivator CBP and blocking its recruitment into transcription initiation complexes on TGF-β-responsive elements, the KSHV lytic protein, K-bZIP, also inhibits TGF-β signaling.\textsuperscript{80}

3.6 | Human T-cell Lymphotropic virus type 1

HTLV-1, the causative agent of adult T-cell leukemia (ATL), has also been involved in TGF-β signaling interruption (Figure 7).\textsuperscript{81-83} Reports indicate the HTLV-1 Tax protein overexpresses high levels of TGF-β mRNA and protein in mice models.\textsuperscript{84} However, Tax was reported to repress the TGF-β-mediated transcriptional activation and growth inhibition, via competitive interactions with both SMAD factors and the transcriptional co-activator p300, and also by preventing the SMADs complex formation and binding to target sequences.\textsuperscript{81} Furthermore, Tax inhibits TGF-β signaling by JNK/c-Jun activation and then the
association of c-Jun with SMAD3 and suppressing its DNA binding ability, which may significantly affect ATL leukemogenesis. Similar to natural Tregs, ATL cells represent a CD4⁺CD25⁺ phenotype, and two-thirds of ATL cases express FoxP3 suggesting that the cancer may root from HTLV-1-infected natural Treg cells; nonetheless, recently Zhao found the HTLV-1 bZIP factor (HBZ) interacts with SMAD3 and p300, forming a ternary complex that leads to increased association of SMAD3 and p300, enhanced signaling, and thereafter, induced Foxp3 expression in naive T cells, which allows the virus to convert infected T cells into Treg cells. Additionally, they reported that
HBZ could overcome the Tax-induced inhibition. Taken together, these interactions proposed that the modulation of TGF-β signaling may play a critical role in the HTLV-1-associated leukemogenesis.

4 | TUMOR-ASSOCIATED VIRUSES AND TGF-β SIGNALING

4.1 | Cytomegalovirus

CMV is a Herpesvirus associated with several tumors, such as colon, breast, and prostate cancers, acting as an oncomodulator by which enhance tumor growth through interfering with cell signaling in an established malignancy. CMV also associates with poor graft outcome in renal disorders, and can result in miscarriage, stillbirth, and retardation of fetal growth in pregnancy. Investigations showed the expression of TGF-β in a variety of cells and tissues during CMV infection; brain samples of AIDS patients who had CMV encephalitis were indicated to have viral inclusions co-localized with TGF-β protein in cells with astrocyte-specific glial filaments. CMV increases in vitro expression of TGF-β mRNA and protein from infected astrocytes, fibroblasts, and osteosarcoma cells. Furthermore, in vitro transient expression of the CMV immediate early 1 and 2 (IE1, IE2) genes also induces TGF-β expression. For instance, the IE2 stimulates TGF-β expression in human glioma cells, via interacting with the Egr-1 DNA-binding protein. Additionally, CMV also augments the

**FIGURE 8** A schematic illustration of the major SARS-CoV proteins and corresponding targets, by which the virus modulates the TGF-β signaling pathway

**FIGURE 9** A schematic illustration of the major influenza A proteins and corresponding targets, by which the virus modulates the TGF-β signaling pathway
| Viral pathogen | Viral Factor | Mechanism/Effect | References |
|---------------|-------------|-----------------|------------|
| HCV Core | • upregulated TGF-β expression, both in vivo and in vitro.<br>• suppressed TGF-β-induced p21 expression by acting through the TGF-β-responsive element (TβRE) positioned in the p21 promoter region.<br>• inhibited SMAD3-mediated transcriptional activation via reducing the SMAD3 DNA binding ability.<br>• activated TGF-β protein through the induction of THBS.<br>• upregulated TGF-β expression by enhancing GRP94.<br>• downregulated TGF-β expression via reducing AP-1.<br>• repressed TGF-β mediated-apoptosis via inducing the PI3K-Akt survival pathway by PTEN inhibition.<br>• blocked TGF-β signaling and P21 expression through TGFβRII suppression.<br>• suppressed SMAD3-mediated transcriptional activation via decreasing the SMAD3 DNA binding activity.<br>• increased TGF-β signaling by the inhibition of SMURF2.<br>• TGF-β overexpression, mediated by ROS-induced p38, JNK, ERK MAPK pathways induction leading to NF-κB activation.<br>• extracellular matrix (ECM) deposition by JNK/pSmad3-mediated PAl-1 upregulation.<br>• upregulated TGF-β through induced ER stress responses. | | 28, 32, 35, 29, 24, 24, 38, 31, 33, 30, 37, 26 |
| HBV HBx | • induction of the JNK/pSmad3L/c-Myc tumor suppressor pathway in the early stages of liver carcinogenesis.<br>• upregulated signaling through PPM1a downmodulation.<br>• upregulated TGF-β expression by acting through the Egr transcription factors binding site.<br>• stabilized SMADs complex by interacting with SMAD4.<br>• inhibited TGF-β induced-apoptosis via upregulating the PI3-kinase signaling pathway.<br>• suppressed TGF-β induced-apoptosis through absorbing mir-15a that in turn targets and increases SMAD7. | | 43, 7, 45, 46, 47, 48 |
| HPV HPV16 E6 | • enhanced TGF-β expression through the interaction with the Sp1-binding site located in the TGF-β promoter.<br>• blocked signaling through the inhibition of SMAD3 DNA binding activity.<br>• interrupted anti-growth effects by interfering with the cyclin-dependent kinase inhibitors p21cip1, p27cip1, and p15ink4b.<br>• increased TGF-β levels via the interaction with the Sp1-binding site located in the TGF-β promoter.<br>• blocked signaling through the downregulation of TGFβRII, and by decreasing SMAD2 phosphorylation and SMAD4 nuclear translocation. | | 52, 54, 57, 52, 55 |
| HPV16 E5 | • repressed SMAD/CBP binding site located in the TGFβ promoter. | | 52 |
| HPV18 E6 | • repressed SMAD3/3L/SAPK pathway. | | 52 |
| HPV8 and MmuPV1 E6 | • enhanced TGF-β expression through the interaction with the Sp1-binding site located in the TGF-β promoter. | | 52 |
| HPV5 E6 | • blocked SMAD/CBP-p300 complex formation by the induction of NF-κB that competitively interacts with CBP-p300. | | 56, 66 |
| EBV LMP-1 | • upmodulated Id1 expression through ATF3 suppression. | | 47 |
| EBNA-1 | • repressed SMAD3/SMAD4 complex formation by vIRF-1 interaction with both SMAD3/4. | | 48, 49 |
| BARF1 | • inhibited the tumor suppressor, PTPRK, in Hodgkin lymphoma cells by decreasing SMAD2 levels. | | 48, 49 |
| KSHV LANA | • downregulated TGFβRII by LANA-mediated histone methylation and deacetylation of TGFβRII promoter. | | 77 |
| vFLIP | • downregulated SMAD2 through the induction of oncogenic miR-17-92. | | 75 |
| vCyC | • downmodulated SMAD2 via the induction of oncogenic miR-17-92. | | 75 |
| miR-K12-11 | • suppressed SMAD5 by targeting SMAD5 mRNAs. | | 76 |
| miR-K10 | • downregulated TGFβRII through targeting TGFβRII mRNAs. | | 77 |
| viRf-1 | • repressed TBS1 by targeting TBS1 mRNAs. | | 78 |
| K-bZIP | • inhibited SMAD3/SMAD4 complex formation by vIRF-1 interaction with both SMAD3/4. | | 79 |
| HTLV-1 Tax | • upregulated TGF-β mRNA and protein in mice model. | | 84 |
| HBZ | • increased SMAD/p300 complex formation by HBZ-mediated ternary complex formation (SMAD3-HBZ-p300). | | 82 |
| CMV IE1 | • enhanced TGF-β expression in vitro. | | 88,89 |
| IE2 | • activated latent TGF-β via increasing matrix metalloprotease 2 (MMP-2). | | 85 |
| • promoted TGF-β expression through interacting with the Egr-1 DNA-binding protein in human glioma cells. | | 90 |
| • activation of latent TGF-β by inducing matrix metalloprotease 2 (MMP-2). | | 85 |
| • repressed EVT proliferation and invasion by disrupting the TGF-β signaling pathway. | | 86, 85,93 |
| • manipulated both TGF-β protein and signaling in renal transplant patients. | | 84 |
| • increased collagen IV expression in the placenta, as a result of avβ6 integrin-mediated TGF-β protein and signaling activation. | | 94 |
| HIV-1 gp160 | • elevated TGF-β mRNA expression and protein secretion in human PBMC. | | 98 |
| gp120 | • exacerbated HCV-caused liver disease by upregulating TGF-β expression. | | 99 |

(Continues)
production of this cellular immune suppressive cytokine in several tumor cell types (e.g., glioblastoma, leukemia, and osteosarcoma cells), affecting host immune responses toward these tumor cells.

CMV DNA and proteins were shown to be correlated with increased TGF-β and arterial intimal thickening in tubuli and arterial endothelium in CMV infected human kidney allografts compared with uninfected allografts. Similarly, enhanced urinary excretion of TGF-β has also been found in urine samples of CMV-positive renal transplant patients, which was associated with exacerbated fibrosis in biopsies taken from patients. This association of CMV infection with enhanced TGF-β expression reinforces the possibility that CMV may promote renal allograft rejection through CMV infection-induced TGF-β leading to fibrosis inside the allograft; CMV-infected human renal tubular epithelial cells that were exposed to TGF-β in vitro, developed EMT, after which the cells also activated extracellular latent form of TGF-β. This effect may root from the induction of a known activator of latent TGF-β, matrix metalloprotease 2 (MMP-2), by IE1 and IE2. Moreover, manipulated TGF-β signaling by CMV may also be involved in defective placental development, and then in pregnancy-associated complications. In CMV-infected placental blood vessels, the virus infected endothelial cells induced the expression of TGF-β (and TGF-β signaling) and collagen IV through increasing αvβ6 integrin production, proposing that CMV infection of the placenta may modify ECM, enabling the virus to translocate throughout the placenta to infect the fetus. Extravillous cytotrophoblast (EVT) invasion into the endometrium is a critical event to remodel the uterine arteries during normal pregnancy, whose dysfunction results in impaired placental blood flow. An in vitro study revealed that CMV may inhibit EVT proliferation and invasion by dysregulating the TGF-β pathway; so that, the levels of TGF-β, SMAD2, SMAD3, and SMAD4 mRNA were significantly increased, but those of TGFβRI, TGFβRII, SMAD7, MMP2, and MMP9 were reported to be decreased by HCMV infection.

HIV-1, a lentivirus, whose infection is associated with an increased risk of developing cancers of other infectious agents, also may affect TGF-β signaling. Elevated concentrations of active TGF-β were recorded in patients with HIV-1 infection. Furthermore, HIV-1 gp160 increases the levels of TGF-β in human PBMC, and also inactivated HIV and gp120 elevate TGF-β expression, by which enhance HCV replication, and then, exacerbate HCV-caused liver disease.

### 5 | OTHER HUMAN VIRUSES

Viral pathogens currently not associated with oncogenesis also modulate the TGF-β pathway. Severe acute respiratory syndrome (SARS) coronavirus (CoV), a RNA virus known to cause outbreak of SARS disease, targets TGF-β signaling; SARS-CoV papain-like protease (PLpro) stimulates the TGF-β mRNA and protein production and pro-fibrotic genes expression by the p38 MAPK and ERK1/2-mediated pathways in human promonocytes (Figure 8). In human lung epithelial cells and mouse models, SARS-CoV PLpro also upregulated the level of Egr-1 through the ROS-mediated TGFβRI signaling, leading to the increase in TGF-β production by direct Egr-1 interacting with the Egr-1 binding site located in the TGF-β promoter region. SARS-CoV PLpro similarly upmodulated p38 MAPK/STAT3-mediated expression of Type I collagen in vitro and in vivo, mediated by non-SMAD TGF-β signaling including STAT6 activation, correlated with upregulated pulmonary pro-fibrotic responses. Furthermore, SARS-CoV nucleocapsid (N) protein inhibited the formation of SMAD3/4 complex, resulting in blocked TGF-β-induced apoptosis in SARS-CoV-infected host cells. Meanwhile, N protein also interacted with SMAD3 and increased SMAD3-p300 complex formation, contributing to promoted plasminogen activator inhibitor-1 (PAI-1) levels, and hence, tissue fibrosis, suggesting novel therapeutic targets for SARS treatment.

Influenza A is a RNA virus, pathogenic for respiratory tract that was reported to intensify fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF) through an αvβ6 integrin dependent TGF-β activity. In fact, pulmonary infection with H1N1 virus can result in the activation of SMAD2/3 and also can increase toll like receptor 3 (TLR3) stimulation, which in turn enhances RhoA activity, a novel mechanism contributing to αvβ6 integrin-mediated TGF-β activation, resulting in enhanced epithelial apoptosis, collagen deposition, and then pulmonary fibrosis (Figure 9). In addition, both influenza virus
and bacterial neuraminidases (NA) directly activate latent TGF-β by removing sialic acid motifs from the latent form in cell free systems.\textsuperscript{103} Interestingly, through the activation of TGF-β, influenza A virus NA upregulates host adhesion molecules required for bacterial binding, resulting in elevated bacterial loading in lung, a phenomenon that was inhibited after the suppression of TGF-β signaling, proposing TGF-β and cellular adhesins as potential molecular targets for the prevention of postinfluenza bacterial pneumonia.\textsuperscript{106}

Adenovirus (AV), an infectious agent of respiratory tract,\textsuperscript{107} also influences TGF-β signaling. Adenovirus E1A reduces the level of TGFβRII mRNA and protein in adenovirus-infected cells.\textsuperscript{108} The E1A protein also inhibits TGF-β-induced cell growth arrest by its binding to p300 and then preventing TGF-β-mediated expression of the cyclin-dependent kinase inhibitors, p15 and p21.\textsuperscript{109} Moreover, E1A interacts with SMAD3 and then further represses the formation of SMAD3/p300 complex.\textsuperscript{110} Human hepatocellular carcinoma cells (Huh-7) infected with AV were also reported to be insensitive to TGF-β-induced apoptosis; the E1A protein and E1B-19 K were required for this resistance.\textsuperscript{111}

RSV, a common cause of infant bronchiolitis and pneumonia,\textsuperscript{112,113} increases TGF-β production and signaling in human epithelial cells to facilitate its infection. RSV also induces TGF-β and the TGF-β dependent SMAD-2/3 signaling in macrophages.\textsuperscript{114}

Further, infection of human hepatocytes with ebola virus (EBOV), a major cause of hemorrhagic fevers, enhanced TGF-β secretion, suggested to activate TGF-β-regulated signaling pathways, ERK1/2, p38 MAPK, and SMAD3, leading to the induction of an EMT-like phenotype in infected cells.\textsuperscript{115} Similarly, reovirus also stimulates TGF-β signaling in murine model of encephalitis in vivo, by inducing TGFβRI expression, and by activating SMAD3 factor, contributing to neuronal survival.\textsuperscript{116}

6 | CONCLUSIONS

TGF-β signaling is a critical target of viruses during course of tumorigenesis. It also seems to be involved in viral-induced pulmonary fibrosis, renal diseases, and pregnancy-associated complications. Viruses utilize various mechanisms to modulate this pathway, which appears to be through (Table 1, Figure 1) (1) modulation of either TGF-β protein expression or activation, (2) modulation of the TGF-β receptors or SMADs factors (by interfering with their levels and functions), (3) modulation of none-SMAD cascades, and (4) indirect interaction by the modulation of transcriptional co-activator/repressor and regulators of the pathway. Two major TGF-β-regulated events that are modulated by most, if not all, viruses are exacerbated cell growth and induction of fibrosis. Hence, as a pivotal pathway modified by viruses in particular in cancer, TGF-β signaling should be assessed as an appropriate therapeutic target. So that, TGF-β antibodies, antisense oligonucleotides, and small molecules targeting TGFβRI have demonstrated therapeutic potentials.\textsuperscript{8}

CONFLICT OF INTEREST

None declared.

REFERENCES

1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118(12):3030-3044.
2. Fiorina L, Ricotti M, Vanoli A, et al. Systematic analysis of human oncocogenic viruses in colon cancer revealed EBV latency in lymphoid infiltrates. Infect Agents Cancer. 2014;9(1):18.
3. White MK, Pagano JS, Khalili K. Viruses and human cancers: a long road of discovery of molecular paradigms. Clin Microbiol Rev. 2014;27(3):463-481.
4. Zuylen WJ, Rawlinson WD, Ford CE. The Wnt pathway: a key network in cell signalling dysregulated by viruses. Rev Med Virol. 2016;26(5):340-355.
5. Fabregat I, Fernandez J, Mainez J, Sancho P. TGF-beta signaling in cancer treatment. Curr Pharm Des. 2014;20(17):2934-2947.
6. Fu S, Zhou R-r, Li N, Huang Y, Fan X-G, Hepatitis B Virus X protein in liver tumor microenvironment. Tumor Biol. 2016;37(12):15371-15381.
7. Liu Y, Xu Y, Ma H, et al. Hepatitis B virus X protein amplifies TGF-β promotion on HCC motility through down-regulating PPM1a. Oncotarget. 2016;7(22):33125-33135.
8. Syed V. TGF-β signaling in cancer. J Cell Biochem. 2016;117(6):1279-1287.
9. Ikushima H, Miyazono K. TGF-β signaling: a complex web in cancer progression. Nat Rev Cancer. 2010;10(6):415-424.
10. Imamura T, Oshima Y, Hikita A. Regulation of TGF-β family signaling by ubiquitination and deubiquitination. J Biochem. 2013;154(6):481-489.
11. Budi EH, Duan D, Derynck R. Transforming growth factor-β receptors and Smads: regulatory complexity and functional versatility. Trends Cell Biol. 2017;27(9):658-672.
12. Massagué J. TGFβ signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616-630.
13. Neuzillet C, Tijeras-Rabaillard A, Cohen R, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015;147:22-31.
14. Verga-Gérard A, Porcherot M, Meyniel-Schicklin L, André P, Lotteau V, Perrin-Cocon L. Virus/human interactome identifies SMURF2 and the viral protease as critical elements for the control of TGF-β signaling. FASEB J. 2013;27(10):4027-4040.
15. Huang JJ, Blobe GC. Dichotomous roles of TGF-β in human cancer. Biochem Soc Trans. 2016;44(5):1441-1454.
16. Levy L, Hill CS. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 2006;17(1):41-58.
17. Bornstein S, White R, Malkoski S, et al. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest. 2009;119(11):3408-3419.
18. Papageorgis P. TGFβ signaling in tumor initiation, epithelial-to-mesenchymal transition, and metastasis. J Oncol. 2015;2015:1-15.
19. Mu Y, Gudey SK, Landström M. Non-Smad signaling pathways. Cell Tissue Res. 2012;347(1):11-20.
20. Itoh S, ten Dijke P. Negative regulation of TGF-β receptor/Smad signal transduction. Curr Opin Cell Biol. 2007;19(2):176-184.
21. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13(2):123-135.
22. Fabregat I, Moreno-Cáceres J, Sánchez A, et al. TGF-β signalling and liver disease. FEBS Journal. 2016;283(12):2219-2232.
23. Shirai Y, Kawata S, Tamura S, et al. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer. 1994;73(9):2275-2279.
24. Lee MN, Jung EY, Kwun HJ, et al. Hepatitis C virus core protein represses transforming growth factor-β1 transcription. J Med Virol. 2004;72(1):52-59.

25. Chusri P, Kumthip K, Hong J, et al. HCV induces transforming growth factor-β1 production through the generation of reactive oxygen species in a nuclear factor-kB-dependent manner. Gastroenterology. 2010;138(7):2509-2518. e1

26. Lin W, Tsai WL, Shao RX, et al. Hepatitis C virus regulates transforming growth factor β1 production through the generation of reactive oxygen species in a nuclear factor-kB-dependent manner. J Hepatol. 2013;59(6):1160-1168.

27. Kim J, Hur W, Yang F, et al. Regulation of transforming growth factor beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J Clin Investig. 1996;97(2):388

28. Matsuzaki K, Murata M, Yoshida K, et al. Chronic inflammation associated with hepatitis B virus in patients with chronic hepatitis B. J Hepatol. 2006;42(4):708-714.

29. Benzoubir N, Lejamtel C, Battaglia S, et al. HCV core variants repress the p21 promoter through inhibition of a TGF-β-activated kinase pathway. PLoS one. 2010;5(4):e10167.

30. Shin E, Jee MH, Hong KY, Park JH, et al. New mechanism of hepatic fibrogenesis: hepatitis C virus infection induces transforming growth factor β1 production through glucose-regulated protein 94. J Virol. 2016;90(6):3044-3055.

31. Lin W, Tsai WL, Shao RX, et al. Hepatitis C virus regulates transforming growth factor β1 production through the generation of reactive oxygen species in a nuclear factor-kB-dependent manner. Gastroenterology. 2010;138(7):2509-2518. e1

32. Lee MN, Jung EY, Kwun HJ, et al. Hepatitis C virus core protein represses transforming growth factor-β1 transcription. J Med Virol. 2004;72(1):52-59.

33. Lee MN, Knisley SE, Knisley KE, et al. Hepatitis C virus core protein represses the p21 promoter through inhibition of a TGF-β pathway. J Gen Virol. 2002;83(9):2145-2151.

34. Cheng PL, Chang M-H, Chao C-H, Lee Y-HW. Hepatitis C viral proteins interact with Smad3 and differentially regulate TGF-β/Smad3-mediated transcriptional activation. Oncogene. 2004;23(47):7821-7838.

35. Bauer J, Sporn JC, Cabral J, Gomez J, Jung B. Effects of activin and TGF-β1 on p21 in colon cancer. J Virol. 2000;74(2):901-909.

36. Braun J, Sporn JC, Cabral J, Gomez J, Jung B. Effects of activin and TGF-β1 on p21 in colon cancer. J Virol. 2000;74(2):901-909.

37. Pavlo N, Battaglia S, Boucreux D, et al. Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-β pathway. Oncogene. 2005;24(10):6119-6132.

38. Battaglia S, Benzoubir N, Noblet S, et al. Liver cancer-derived hepatitis C virus core proteins shift TGF-β responses from tumor suppression to epithelial-mesenchymal transition. PLoS one. 2009;4(2):e3455

39. Sato M, Murata M, Yoshida K, et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor β signaling, promoting cirrhosis and hepatocarcinogenesis. Hepatology. 2007;46(1):48-57.

40. Cheng D, Zhang L, Yang G, et al. Hepatitis C virus NS5A drives a PTEN-Pi3K/Akt feedback loop to support cell survival. Liver Int. 2015;35(6):1682-1691.

41. Shin E-C, Sung PS, Park S-H. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16(8):509-522.

42. Li Y-W, Yang F-C, Lu H-Q, Zhang J-S. Hepatocellular carcinoma and hepatitis B surface protein. World J Gastroenterol. 2016;22(6):1943-1952.

43. Tu T, Budzinska MA, Shackel NA, Urban SHBV DNA. Integration: molecular mechanisms and clinical implications. Virus. 2017;9(4):75

44. Wu YH, AI X, Liu FY, Liang HF, Zhang BX, Chen XP. c-Jun N-terminal kinase inhibitor favors transforming growth factor-β to antagonize hepatitis B virus X protein-induced cell growth promotion in hepatocellular carcinoma. Mol Med Rep. 2016;13(2):1345-1352.

45. Murata M, Matsuoka K, Yoshida K, et al. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-β1 signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology. 2009;49(4):1203-1217.

46. Yang P, Markowitz GJ, Wang X-F. The hepatitis B virus-associated microenvironment in hepatocellular carcinoma. Nat Rev Rev. 2014;1(3):396-412.

47. Yoo Y, Ueda H, Park K, et al. Regulation of transforming growth factor-β1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J Clin Investig. 1996;97(2):388

48. Lee DK, Park SH, Yi Y, et al. The hepatitis B virus encoded oncoprotein pX amplifies TGF-β family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis. Genes Dev. 2001;15(4):455-466.

49. Li Y, Jia T, Huang Y, Liu W, Li Z, Ye X. Virus regulates apoptosis and tumorigenesis through the microRNA-15a-Smad7-transforming growth factor beta pathway. J Virol. 2015;89(5):2739-2749.

50. Liu N, Jia T, Jia T, et al. Hepatitis B virus inhibits apoptosis of hepatoma cells by sponging the microRNA 15a/16 cluster. J Virol. 2013;87(24):13370-13378.

51. Dadashi M, Eslami G, Faghighi E, et al. Detection of human papillomavirus type 16 in epithelial ovarian tumors samples. Arch Clin Infect Dis. 2017 January;12(1):e39666

52. Faghighi E, Akbari A, Adjaminehzad-Fard F, Mokhtari-Azad T. Transcriptional regulation of E-cadherin and oncoprotein E7 by valproic acid in HPV positive cell lines. Iran J Basic Med Sci. 2016;19(6):601-607.

53. Zhu H, Luo H, Shen Z, Hu X, Sun L, Zhu X. Transforming growth factor-β1 in carcinogenesis, progression, and therapy in cervical cancer. Tumor Biol. 2016;37(1):7075-7083.

54. Ki K-D, Tong S-Y, Huh C-Y, Lee J-M, Lee S-K, Chi S-G. Expression and mutational analysis of TGF-β/Smad signaling in human cervical cancers. J Gynecol Oncol. 2009;20(2):117-121.

55. Lee DK, Kim B-C, Kim YJ, Cho E-a, Satterwhite DJ, Kim S-J. The human papilloma virus E7 oncoprotein inhibits transforming growth factor-β signaling by blocking binding of the Smad complex to its target sequence. J Biol Chem. 2002;277(41):38557-38564.

56. French D, Belleudi F, Mauro MV, et al. Expression of HPV16 E5 down-modulates the TGFbeta signaling pathway. Mol Cancer. 2013;12(1):38

57. Favre-Bonvin A, Reynaud C, Kretz-Remy C, Jalipot P. Human papillomavirus type 18 E6 protein binds the cellular PDZ protein TIP-2/GIPC, which is involved in transforming growth factor β signaling and triggers its degradation by the proteasome. J Virol. 2005;79(7):4229-4237.

58. McLaughlin-Drubin ME, Munder K. The human papillomavirus E7 oncoprotein. Virology. 2009;384(2):335-344.

59. Mendoza J-A, Jacob Y, Cassonnet P, Favre M. Human papillomavirus type 5 E6 oncoprotein represses the transforming growth factor β signaling pathway by binding to SMAD3. J Virol. 2006;80(24):12420-12424.

60. Meyers JM, Uberoi A, Grace M, Lambert PF, Munger K. Cutaneous HPV8 and MmuPV1 E6 proteins target the NOTC and TGF-β tumor suppressors to inhibit differentiation and sustain keratinocyte proliferation. PLoS Pathog. 2017;13(1):e1006171

61. Kemple E, Robertson ES. Epstein-Barr virus latency: current and future perspectives. Curr Opin Virol. 2015;14:138-144.

62. Faghighi E, Sarem MR, Mahabadi M, Akbari H, Saberfar E. Prevalence and characteristics of Epstein-Barr virus-associated gastric cancer in Iran. Arch Iran Med. 2014;17(11):767-770.

63. Mahabadi M, Faghighi E, Alshiri GH, Atae MH, Atae AA. Detection of Epstein-Barr virus in synovial fluid of rheumatoid arthritis patients. Electron Physician. 2016;8(3):2181-2186.
78. Samols MA, Skalsky RL, Maldonado AM, et al. Identification of cellular protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-beta 1-mediated growth inhibition in EBV-positive B cells. J Immunol. 1999;155(3):1047-1056.

79. Kim DH, Chang MS, Yoon CJ, et al. Epstein-Barr virus (EBV) latency type III superantigen BARF1 regulates human trophoblast invasion/differentiation and is down-regulated in preeclampsia. J Biol Chem. 2012;287(18):17388-17397.

80. Choi HS, Jain V, Krueger B, et al. Kaposi's sarcoma associated herpesvirus type 1 tax inhibits transforming growth factor-beta signaling by blocking the association of Smad proteins with Smad-binding element. J Biol Chem. 2002;277(37):33766-33775.

81. Lo AK, Dawson CW, Lo KW, Yu Y, Young LS. Upregulation of Id1 by Epstein-Barr virus-encoded LMP1 confers resistance to TGF-beta-mediated growth inhibition. Mol Cancer. 2010;9(1):155.

82. Borges ÁH, Silverberg MJ, Wentworth D, et al. Predicting risk of cardiovascular disease using atherosclerosis risk in communities study data and plasma transforming growth factor-beta level. J Cereb Blood Flow Metab. 2017;37(10):2223-2231.

83. Turrini R, Merlo A, Martorelli D, et al. A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors. Oncol Rep. 2015;34(3):1467-1475.

84. Lei X, Zuo Y, Jones T, Bai Z, Huang Y, Gao S-JA. Kaposi's sarcoma-associated herpesvirus microRNA and its variants target the transforming growth factor beta pathway to promote cell survival. J Biol Chem. 2012;287(20):16964-16974.

85. Choi HS, Jain V, Krueger B, et al. Kaposi's sarcoma-associated herpesvirus (KSHV) induces the oncogenic miR-17-92 cluster and down-regulates TGF-beta signaling. PLoS Pathog. 2015;11(11):e1005255.

86. Liu Y, Sun R, Lin X, Liang D, Deng Q, Lan K. Kaposi's sarcoma-associated herpesvirus microRNA miR-K12-11 attenuates transforming growth factor beta signaling through suppression of SMAD5. J Virol. 2012;86(3):1372-1381.

87. Di Bartolo DL, Cannon M, Liu YF, et al. KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor. Blood. 2008;111(9):4731-4740.

88. Samols MA, Skalsky RL, Maldonado AM, et al. Identification of cellular genes targeted by KSHV-encoded microRNAs. PLoS Pathog. 2007;3(5):e65.

89. Seo T, Park J, Choi J. Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 1 inhibits transforming growth factor-beta signaling. Cancer Res. 2005;65(5):1738-1747.

90. Tomita M, Choe J, Tsukazaki T, Mori N. The Kaposi's sarcoma-associated herpesvirus K-BZIP protein represses transforming growth factor-beta signaling through interaction with CREB-binding protein. Oncogene. 2004;23(50):8272-8281.

91. Lee DK, Kim B-C, Brady JN, Jeang K-T, Kim S-J, Human T. Cell line lymphotropic virus type 1 tax inhibits transforming growth factor-beta signaling.
100. Li S-W, Wang C-Y, Jou Y-J, et al. SARS coronavirus papain-like protease induces Egr-1-dependent up-regulation of TGF-β1 via ROS/p38 MAPK/STAT3 pathway. Sci Rep. 2016;6(1):25754.

101. Wang C-Y, C-YL, Li S-W, et al. SARS coronavirus papain-like protease up-regulates the collagen expression through non-Samd TGF-β1 signaling. Sci Rep. 2016;6(1):25754.

102. Li SW, Yang TC, Wan L, et al. Correlation between TGF-β1 expression and proteomic profiling induced by severe acute respiratory syndrome coronavirus papain-like protease. Proteomics. 2012;12(21):3193-3205.

103. Zhao X, Nicholls JM, Chen Y-G. Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-β signaling. J Biol Chem. 2008;283(6):3272-3280.

104. Jolly L, Stavrou A, Vanderstoken G, et al. Influenza promotes collagen deposition via αvβ6 integrin-mediated transforming growth factor β activation. J Biol Chem. 2014;289(51):35246-35263.

105. Carlson CM, Turpin EA, Moser LA, et al. Transforming growth factor-β: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis. PLoS Pathog. 2010;6(10):e1001136.

106. Li N, Ren A, Wang X, et al. Influenza viral neuraminidase primes bacterial coinfection through TGF-β1-mediated expression of host cell receptors. Proc Natl Acad Sci. 2015;112(1):238-243.

107. Scott MK, Chommanard C, Lu X, et al. Human adenovirus associated with severe respiratory infection, Oregon, USA, 2013–2014. Emerg Infect Dis. 2016;22(6):1044-1051.

108. Tarakanova VL, Wold WS. Transforming growth factor β1 receptor II is downregulated by E1A in adenovirus-infected cells. J Virol. 2003;77(17):9324-9336.

109. Datto MB, PP-c H, Kowalik TF, Yingling J, Wang X-F. The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B. Mol Cell Biol. 1997;17(4):2030-2037.

110. Nishihara A, Hanai J-I, Imamura T, Miyazono K, Kawabata M. E1A inhibits transforming growth factor-β signaling through binding to Smad proteins. J Biol Chem. 1999;274(40):28716-28723.

111. Tarakanova VL, Wold WS. Adenovirus E1A and E1B-19K proteins protect human hepatoma cells from transforming growth factor β1-induced apoptosis. Virus Res. 2010;147(1):67-76.

112. Faghihloo E, Rezaie F, Salimi V, et al. Molecular epidemiology of human respiratory syncytial virus in Iran. Acta Virol. 2011;55(1):81-83.

113. Salimi V, Ramezani A, Mirzaei H, et al. Evaluation of the expression level of 12/15 lipoxygenase and the related inflammatory factors (CCL5, CCL3) in respiratory syncytial virus infection in mice model. Microb Pathog. 2017 Aug;109:209-213.

114. Pokharel SM, Shil NK, Bose S, Autophagy, TGF-β, and SMAD-2/3 signaling regulates interferon-β response in respiratory syncytial virus infected macrophages. Front Cell Infect Microbiol. 2016;6.

115. Kindrachuk J, Wahl-Jensen V, Safronetz D, et al. Ebola virus modulates transforming growth factor β signaling and cellular markers of mesenchyme-like transition in hepatocytes. J Virol. 2014;88(17):9877-9892.

116. Beckham JD, Tuttle K, Tyler KL. Reovirus activates transforming growth factor β and bone morphogenetic protein signaling pathways in the central nervous system that contribute to neuronal survival following infection. J Virol. 2009;83(10):5035-5045.

How to cite this article: Mirzaei H, Faghihloo E. Viruses as key modulators of the TGF-β pathway: a double-edged sword involved in cancer. Rev Med Virol. 2018;28:e1967. https://doi.org/10.1002/rmv.1967